B7-H3 expression in ductal and lobular breast cancer and its association with IL-10

Liu,Chuanyong; Liu,Jie; Wang,Jie; Liu,Yan; Zhang,Fang; Lin,Wenli; Gao,Aiqin; Sun,Meili; Wang,Yunshan; Sun,Yuping

doi:10.3892/mmr.2012.1158

B7-H3 expression in ductal and lobular breast cancer and its association with IL-10

Authors:
- Chuanyong Liu
- Jie Liu
- Jie Wang
- Yan Liu
- Fang Zhang
- Wenli Lin
- Aiqin Gao
- Meili Sun
- Yunshan Wang
- Yuping Sun
View Affiliations

Affiliations: Department of Oncology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Department of General Surgery, Jinan Central Hospital, Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Medical Diagnosis Laboratory, Jinan Central Hospital, Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Department of Pharmacy, Jinan Central Hospital, Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
Published online on: October 29, 2012 https://doi.org/10.3892/mmr.2012.1158
Pages: 134-138

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant tumor cell expression of B7-H3, a member of the B7-family that stimulates interleukin-10 (IL-10) secretion, contributes to tumor immune evasion and tumor progression. The aim of this study was to investigate the expression of B7-H3 and IL-10 in ductal and lobular breast cancer tissues. Using immunohistochemistry, B7-H3 and IL-10 protein expression in tumor specimens of primary human breast cancer was investigated. The association between B7-H3 or IL-10 expression and clinicopathological variables was analyzed. The correlation between the expression of B7-H3 and IL-10 was also evaluated. In tumor tissues, the expression of B7-H3 and IL-10 was identified on the cell membrane and in the cytoplasm. Expression of B7-H3 was observed in 90.60% (106/117) of the specimens and 80.34% (94/117) expressed IL-10. Patients with a positive B7-H3 or high IL-10 expression were more likely to have positive lymph node metastasis (N1-3; P=0.018 or 0.035, respectively) and advanced disease (stage II-IV; P=0.011 or 0.039, respectively) compared to those with a negative or low expression. Furthermore, B7-H3 expression was correlated with IL-10 in tumor cells (R=0.545, P=0.000). High B7-H3 expression in human breast cancer tissues may be important in tumor progression and invasiveness. This expression appeared to be correlated with the ability of B7-H3 to promote IL-10 secretion.

View Figures

View References

1	Glass AG, Lacey JV, Carreon JD and Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 99:1152–1161. 2007.
2	Tirapu I, Huarte E, Guiducci C, et al: Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 66:2442–2450. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ugurel S, Uhlig D, Pföhler C, Tilgen W, Schadendorf D and Reinhold U: Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother. 53:551–559. 2004. View Article : Google Scholar : PubMed/NCBI
4	Carreno BM and Collins M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 20:29–53. 2002. View Article : Google Scholar : PubMed/NCBI
5	Khoury SJ and Sayegh MH: The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 20:529–538. 2004. View Article : Google Scholar : PubMed/NCBI
6	Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y and Dong C: Murine B7-H3 is a negative regulator of T cells. J Immunol. 173:2500–2506. 2004. View Article : Google Scholar : PubMed/NCBI
7	Suh WK, Gajewska BU, Okada H, et al: The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 4:899–906. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM and Collins M: Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics. 82:365–377. 2003. View Article : Google Scholar : PubMed/NCBI
9	Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K and Chen L: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
10	Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005. View Article : Google Scholar : PubMed/NCBI
11	Zhang GB, Chen YJ, Shi Q, Ma HB, Ge Y, Wang Q, Jiang Z, Xu Y and Zhang XG: Human recombinant B7-H3 expressed in E. coli enhances T lymphocyte proliferation and IL-10 secretion in vitro. Acta Biochim Biophys Sin (Shanghai). 36:430–436. 2004.PubMed/NCBI
12	Moore KW, de Waal Malefyt R, Coffman RL and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 19:683–765. 2001. View Article : Google Scholar : PubMed/NCBI
13	Akdis CA and Blaser K: Mechanisms of interleukin-10-mediated immune suppression. Immunology. 103:131–136. 2001. View Article : Google Scholar : PubMed/NCBI
14	Woo SU, Bae JW, Yang JH, Kim JH, Nam SJ and Shin YK: Overexpression of interleukin-10 in sentinel lymph node with breast cancer. Ann Surg Oncol. 14:3268–3273. 2007. View Article : Google Scholar : PubMed/NCBI
15	Llanes-Fernández L, Alvarez-Goyanes RI, Arango-Prado Mdel C, et al: Relationship between IL-10 and tumor markers in breast cancer patients. Breast. 15:482–489. 2006.PubMed/NCBI
16	Smith IE: New drugs for breast cancer. Lancet. 360:790–792. 2002. View Article : Google Scholar : PubMed/NCBI
17	Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
18	Crispen PL, Sheinin Y, Roth TJ, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI
19	Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, Wang HT, Lu BF and Zhang XG: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010. View Article : Google Scholar : PubMed/NCBI
20	Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J and Friess H: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 9:4632009. View Article : Google Scholar : PubMed/NCBI
21	Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, Zhao JM, Zhang GB and Zhang XG: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol. 12:457–459. 2006.PubMed/NCBI
22	Ohigashi Y, Sho M, Yamada Y, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
23	Sun Y, Liu J, Gao P, Wang Y and Liu C: Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest. 134:783–788. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G and Zou W: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67:8900–8905. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kryczek I, Zou L, Rodriguez P, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 203:871–881. 2006. View Article : Google Scholar : PubMed/NCBI
26	García-Hernández ML, Hernández-Pando R, Gariglio P and Berumen J: Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology. 105:231–243. 2002.PubMed/NCBI